Every 8-K that Spyre Therapeutics, Inc. (SYRE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SYRE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SYRE filings page.
Spyre Therapeutics, Inc. (SYRE) entered into an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated, as representatives of the underwriters, for a public offering of 4,117,648 common shares at $85.00 per share. The underwriters received a 30-day option to purchase up to 617,647 additional shares. The offering is expected to close on or about October 7, 2026, subject to customary closing conditions. Gross proceeds to Spyre are expected to be approximately $350.0 million before underwriting discounts and commissions and estimated offering expenses. Net proceeds are intended to advance its Gastroenterology, Rheumatology and Dermatology programs, including preclinical studies, clinical trials, manufacturing and Phase 3 readiness, and a new program to advance SPY072 into late-stage development for hidradenitis suppurativa. Proceeds may also support general infrastructure, potential in-licensing, acquisitions or investments in businesses, technologies, products or assets, ongoing research and development, working capital and other general corporate purposes.
Spyre Therapeutics, Inc. (SYRE) reported positive Part A induction topline data from its Phase 2 SKYLINE trial of SPY003, an anti-IL-23 antibody for moderately-to-severely active ulcerative colitis. SPY003 met the primary endpoint with a 10.0‑point reduction in Robarts Histopathology Index (RHI) at Week 12 (p<0.0001), alongside clinical remission and endoscopic improvement rates the company highlights as in line with the IL‑23 class.
The 10.0‑point RHI reduction was similar to previously reported reductions of 9.2 for SPY001 and 10.7 for SPY002, and the company states these are among the largest improvements seen in ulcerative colitis studies. In 44 SPY003 patients, 43% experienced treatment‑emergent adverse events, with 11% severe adverse events, 1 drug‑related adverse event, no drug‑related serious adverse events, and no deaths. Part B of SKYLINE, testing pairwise combinations of SPY001, SPY002 and SPY003, is enrolling, with topline induction data expected in 2027 and additional readouts from other IBD and immunology programs expected between late 2026 and early 2028.
Spyre Therapeutics, Inc. (SYRE) reported topline data from the rheumatoid arthritis (RA) sub-study of its Phase 2 SKYWAY basket trial of TL1A antibody SPY072. In patients with moderate to severely active RA, SPY072 Low Dose achieved a statistically significant improvement in the primary endpoint, change from baseline in DAS28-CRP at Week 12 versus placebo. High and Low Dose arms also showed nominally significant advantages on key secondary and exploratory endpoints, including ACR20 and ACR50 response rates. SPY072 was well tolerated, with overall adverse event rates similar to placebo and no drug-related serious adverse events. The company stated that while the magnitude of effect did not meet its internal threshold to prioritize SPY072 as a monotherapy in RA, the data provide proof-of-mechanism for TL1A and support its potential in other autoimmune diseases and as a combination component. Spyre highlighted upcoming topline readouts across its I&I pipeline through 2027, including SPY003 in ulcerative colitis, additional SPY072 sub-studies in psoriatic arthritis and axial spondyloarthritis, and a combination study of SPY072 with IL-17A/F in hidradenitis suppurativa.
Spyre Therapeutics reported second quarter 2026 results and advanced its immunology pipeline. Positive topline Phase 2 induction data for SPY001 and SPY002 in ulcerative colitis showed statistically significant Robart’s Histopathology Index reductions of 9.2 and 10.7 points with robust clinical remission and endoscopic improvement rates and a safety profile consistent with in-class comparators.
The SKYWAY Phase 2 basket trial of anti-TL1A antibody SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis has completed enrollment, with proof-of-concept readouts expected from September through late 2026. Cash, cash equivalents and marketable securities were $1,145.3 million as of June 30, 2026, including $435.2 million in net proceeds from an April equity offering, supporting an expected cash runway into the second half of 2029. Net loss for the quarter was $36.2 million, as higher R&D spend of $65.5 million and G&A of $16.1 million were partially offset by a $40.0 million milestone gain on a legacy asset.
Spyre Therapeutics reported positive 12-week induction results from Part A of its Phase 2 SKYLINE trial of SPY002 in moderately-to-severely active ulcerative colitis. SPY002 met its primary endpoint with a statistically significant 10.7-point reduction in Robarts Histopathology Index score at Week 12 (p<0.0001).
Key secondary measures included clinical remission by modified Mayo Score in 33% of patients and endoscopic improvement in 42%. SPY002 was described as well tolerated: 41.7% of the 48 treated patients experienced treatment-emergent adverse events, with two serious events deemed not drug-related, three drug-related adverse events, no adverse events of special interest, and no deaths.
Spyre Therapeutics reported an amendment to its SPY003 license agreement with Paragon Therapeutics. The change expands Spyre’s rights from only inflammatory bowel disease to all therapeutic, prophylactic, palliative and diagnostic uses for SPY003.
This broader license is subject to dosing limits. Spyre will not dose human patients with SPY003 outside inflammatory bowel disease in a clinical trial as part of a combination before June 1, 2028, or as a monotherapy before June 1, 2030, under what is termed the Monotherapy Dosing Restriction.
If Spyre or a Paragon licensee completes a material transaction, such as a change of control, any remaining restrictions outside the original inflammatory bowel disease field will end on June 1, 2028. The full terms are set out in the filed amendment.
Spyre Therapeutics, Inc. reported results from its Annual Meeting of Stockholders held on May 27, 2026. Stockholders elected three Class I directors — Mark McKenna, Cameron Turtle and Laurie Stelzer — to serve until the 2029 annual meeting. They also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers and ratified KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026. In addition, stockholders approved the company’s amended and restated 2016 Employee Stock Purchase Plan, which provides a refreshed framework for employee share purchases. Effective the same day, director Peter Harwin resigned from the board, and the board size was reduced from eight to seven directors; his resignation was not due to any disagreement with the company.
Spyre Therapeutics reported first quarter 2026 results showing continued investment in its pipeline and a larger net loss. Net loss was $69.0 million compared with $44.8 million a year earlier, driven by higher R&D and G&A spending and a swing to other expense from prior-year income.
R&D rose to $60.4 million as manufacturing, clinical trial activity, and headcount increased. G&A reached $15.2 million. The company recorded a $30.0 million gain tied to FDA approval milestones from a prior asset sale, partly offset by higher contingent value right liability, which contributed to $23.4 million in other expense. Spyre ended March 31, 2026 with $741.5 million in cash, cash equivalents, and marketable securities, and reported $1,176.8 million of pro forma cash including April 2026 equity offering proceeds, which it expects will fund operations into the second half of 2029.
Spyre Therapeutics, Inc. entered an underwriting agreement for a public offering of 6,500,000 shares of common stock at $62.00 per share, plus a 30‑day option for 975,000 additional shares that the underwriters fully exercised. The offering, made off an effective Form S-3 shelf, closed with gross proceeds of about $463.5 million before fees and expenses. Spyre plans to use the net proceeds to advance its inflammatory bowel disease and rheumatic disease programs, including preclinical work, clinical trials, manufacturing and Phase 3 readiness for its antibody programs, and for working capital and general corporate purposes.
Spyre Therapeutics, Inc. reported preliminary cash, cash equivalents and marketable securities of approximately $741 million as of March 31, 2026, including $30 million of legacy asset disposition proceeds. About $23 million of these proceeds is expected to be paid to contingent value rights holders in the second quarter of 2026.
These figures are unaudited, subject to closing procedures and may change. Effective April 13, 2026, the company suspended and terminated its at-the-market offering prospectus under its Sales Agreement with TD Securities (USA) LLC, so no further ATM sales will occur unless a new prospectus or registration statement is filed.
Spyre Therapeutics reported positive 12-week induction results from Part A of its Phase 2 SKYLINE trial of SPY001 in moderate-to-severely active ulcerative colitis. SPY001 met the primary endpoint with a statistically significant 9.2-point reduction in Robarts Histopathology Index (p<0.0001).
Key secondary endpoints were also encouraging, with clinical remission by modified Mayo Score in 40% of patients and endoscopic improvement in 51%. Among 43 treated patients, 14% experienced treatment-emergent adverse events and one serious event, which investigators deemed not drug-related, supporting a safety profile consistent with the α4β7 class. Part A recruitment is closed and Part B, including monotherapy and combination cohorts, is now enrolling with additional readouts expected in 2026 and 2027.
Spyre Therapeutics reported fourth quarter and full year 2025 results and highlighted progress across its IBD and rheumatic disease pipeline. The company is running two Phase 2 trials: the SKYLINE platform study in ulcerative colitis and the SKYWAY basket trial in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, with six proof-of-concept readouts planned in 2026.
As of December 31, 2025, Spyre held $756.5 million in cash, cash equivalents, and marketable securities and expects this to fund operations into the second half of 2028. Fourth quarter 2025 R&D expenses were $44.6 million, down from $50.5 million a year earlier, while G&A expenses rose to $12.5 million from $10.8 million.
Other expense in the quarter was $5.4 million, mainly from changes in a contingent value right liability, leading to a quarterly net loss of $62.5 million versus $56.3 million in 2024. For full year 2025, net loss was $155.2 million, compared with $208.0 million in 2024. Spyre also strengthened its balance sheet with an October 2025 underwritten public offering that generated $316.2 million in gross proceeds before $19.8 million in discounts and offering costs.
Spyre Therapeutics, Inc. furnished a current report describing a new press release and an updated corporate presentation made available on its website. These materials include updates on the company’s ongoing clinical trials and the appointment of Kate Tansey Chevlen as Chief Commercial Officer.
The press release (Exhibit 99.1) and the January 2026 corporate presentation (Exhibit 99.2) are provided as exhibits and are treated as furnished rather than filed under securities laws, which affects how they are incorporated into other regulatory documents.
Spyre Therapeutics (SYRE) filed an 8-K announcing two updates: it furnished a press release with financial results for the quarter ended September 30, 2025, and reported positive interim Phase 1 data for SPY003, an extended half-life monoclonal antibody targeting IL‑23.
The first‑in‑human, randomized, double‑blind, placebo‑controlled study enrolled 59 healthy adults across single‑ascending, multiple‑dose, and a Chinese ethnobridging cohort. SPY003 was well tolerated at all dose levels, with two Grade 2 or higher treatment‑emergent adverse events deemed not treatment‑related and no serious adverse events; headache was the only event seen in two or more subjects.
Pharmacokinetic data showed an approximate 85‑day half‑life with dose proportionality and limited intrasubject variability, described as more than three times risankizumab’s published half‑life. The company stated this profile supports the potential for quarterly or twice‑yearly maintenance dosing via a single subcutaneous injection. No apparent impact of anti‑drug antibodies on PK was observed. Spyre noted plans to advance SPY003 into the SKYLINE Phase 2 platform study.
Spyre Therapeutics (SYRE) completed an underwritten public offering of common stock. The company sold 14,864,865 shares at $18.50 per share and granted a 30-day option for up to 2,229,729 additional shares, which the underwriters exercised in full on October 14, 2025. The offering closed on October 15, 2025.
Gross proceeds were approximately $316.2 million before underwriting discounts, commissions, and expenses. Spyre plans to use the net proceeds to advance its inflammatory bowel disease and rheumatic disease programs, including preclinical work, clinical trials, manufacturing, and Phase 3 readiness, as well as for working capital and general corporate purposes. The transaction was conducted off an effective Form S-3 shelf, with Jefferies, TD Securities (USA), Leerink Partners, and Stifel as representatives of the underwriters.
Spyre Therapeutics announced it expects to report approximately $486.2 million in cash, cash equivalents and marketable securities as of September 30, 2025.
The figure is preliminary, has not been audited, and remains subject to completion of financial closing procedures. The company’s independent registered public accounting firm has not audited, reviewed, or performed procedures on this information and does not express assurance. The disclosure was provided under Item 2.02 of an 8-K and is furnished, not filed.